Trial: 201809104

Phase 1 Study of SC-011 as a Single-Agent and in Combination with an Immunoregulatory Molecule in Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC)

Phase

I (Cancer Control)

Principal Investigator

Morgensztern, Daniel

Disease Site

Lung

Learn more about this study at: clinicaltrials.gov